Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19

Despite the global effort to mitigate the spread, coronavirus disease 2019 (COVID-19) has become a pandemic that took more than 2 million lives. There are numerous ongoing clinical studies aiming to find treatment options and many are being published daily. Some effective treatment options, albeit o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sun Bean, Ryoo, Seungeun, Huh, Kyungmin, Joo, Eun-Jeong, Kim, Youn Jeong, Choi, Won Suk, Kim, Yae-Jean, Yoon, Young Kyung, Heo, Jung Yeon, Seo, Yu Bin, Jeong, Su Jin, Park, Dong-ah, Yu, Su-Yeon, Lee, Hyeon-Jeong, Kim, Jimin, Jin, Yan, Park, Jungeun, Peck, Kyong Ran, Choi, Miyoung, Yeom, Joon Sup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2021
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032920/
https://www.ncbi.nlm.nih.gov/pubmed/34409790
http://dx.doi.org/10.3947/ic.2021.0303
Descripción
Sumario:Despite the global effort to mitigate the spread, coronavirus disease 2019 (COVID-19) has become a pandemic that took more than 2 million lives. There are numerous ongoing clinical studies aiming to find treatment options and many are being published daily. Some effective treatment options, albeit of variable efficacy, have been discovered. Therefore, it is necessary to develop an evidence-based methodology, to continuously check for new evidence, and to update recommendations accordingly. Here we provide guidelines on pharmaceutical treatment for COVID-19 based on the latest evidence.

Ejemplares similares